What happens when the cellular machinery making therapeutic proteins slows down? New research in Nature shows why translation ...
An experimental synthetic non-coding RNA drug has reversed signs of systemic sclerosis in patient-derived immune cells and mouse models, with researchers now preparing an IND application to the FDA.
A £20 million high-security facility in Liverpool is set to accelerate drug and vaccine discovery by integrating artificial ...
UK genomics and drug discovery company OutSee has received £50,000 in Innovate UK funding to develop an agentic AI sub-system ...
A compound originally designed to block a cancer-associated protein has demonstrated unexpected benefits for bone health and ...
A new NIH-funded study suggests the GLP-1 receptor agonist semaglutide may slow biological ageing and extend lifespan in ...
Whole-genome sequencing of parasites from Ugandan patients has uncovered a cluster of genetic variants linked to reduced ...
Human biospecimens can bring drug discovery closer to human disease, but their value depends on far more than the sample ...
As spatial proteomics advances, how can researchers find the complex biology of the prostate tumour microenvironment while ...
Steve Hoffmann is Senior Vice President and Chief Preclinical Officer at the Foundation for the National Institutes of Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results